10x Genomics has launched a multi-year partnership with Dana-Farber Cancer Institute to analyze tumor specimens from several hundred patients across major solid tumor types. Employing its Chromium Flex single-cell assay and Xenium spatial platform, the company will generate integrated cellular and spatial maps, linking these molecular profiles to clinical outcomes on therapies such as antibody-drug conjugates, radioligand treatments, bispecific antibodies and immune checkpoint inhibitors. The goal is to uncover biomarkers of treatment response, resistance and disease progression, and to develop a standardized clinical reporting framework that distills complex single-cell and spatial data—such as target expression patterns or immune contexture—into oncologist-ready summaries. This initiative underscores 10x Genomics’ strategy to move beyond purely research use toward diagnostic applications that could influence care decisions in precision oncology.

In parallel, 10x Genomics has partnered with Brigham & Women’s Hospital to profile peripheral blood from 1,000 patients living with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis, alongside healthy controls. Over an extended longitudinal study, investigators will collect blood at routine visits and apply the Chromium Flex single-cell assay to chart immune cell dynamics over time. By correlating these high-resolution immune signatures with disease activity, flare events, remission and therapeutic response, the collaboration aims to identify molecular markers distinguishing responders from non-responders. The teams will also prototype a clinical report format, translating complex immune activation patterns into actionable insights to guide rheumatologists in personalized treatment planning.

To underpin its shift toward diagnostic services, 10x Genomics plans to establish a CLIA-certified laboratory in Pleasanton, California. This facility will provide regulated infrastructure for analytical validation, assay implementation and clinical sample processing, enabling 10x to offer robust, quality-controlled single-cell and spatial assays for future diagnostic tests. By securing CLIA accreditation, the company positions itself to bridge its research-grade platforms with clinical workflows, accelerating the path from discovery to deployment of novel diagnostics in oncology and autoimmune disease.

10x Genomics has also joined forces with the Cancer Research Institute on a multi-phase, AI-powered immuno-oncology program that will generate single-cell and spatial data from over 20,000 samples. The pilot phase, engaging leading labs at the University of Pennsylvania, Stanford and Memorial Sloan Kettering, will process roughly 3,000 specimens to train early AI models and identify predictive microenvironmental features. In the full expansion, 10x’s ultra high-throughput Chromium Flex assay will profile more than 500 million cells, creating one of the world’s largest translational immuno-oncology datasets. This integrated resource aims to elucidate mechanisms of immune response and resistance, refine existing immunotherapies, uncover new therapeutic targets and inform future cancer vaccine development.